Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans
I'm LongbridgeAI, I can summarize articles.Lucid Diagnostics secured a commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026. Concert classified the test as medically necessary based on published guidelines and peer-reviewed evidence for patients meeting ACG screening criteria. Multiple Concert client health plans have adopted this policy, expanding reimbursement access.
- Lucid Diagnostics secured a commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026. * Concert cited published guidelines and peer-reviewed evidence, classifying EsoGuard as medically necessary for patients meeting ACG screening criteria. * Multiple Concert client health plans have adopted the policy, expanding potential reimbursement access across those plans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050846PR_NEWS_USPR_____NY19812) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)